OncoMatch/Clinical Trials/NCT03059173
Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome
Is NCT03059173 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Clomiphene Citrate for polycystic ovary syndrome.
Treatment: Clomiphene Citrate — The main objective will be to check if MyoInositol (MYO) reduces the total resistance rate to Clomiphene Citrate (CC). For this, our study will be controlled, randomized and double blinded. It will include patients with PCOS (polycystic ovary syndrome, defined by the Rotterdam criteria) who wish to become pregnant and are eligible to simple ovulation induction by CC. Half of them will receive MYO + levomefolic acid (5-MTHF) in addition to the CC, while the other half will receive a placebo containing only 5-MTHF in addition to the CC. The MYO supplementation will be initiated at least one month before taking CC and will be continued throughout this treatment until pregnancy or before switching to another type of treatment for ovulation induction if no pregnancy is obtained after 6 ovulatory cycles.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: clomiphene citrate (clomiphene citrate)
Exception: previous treatment with CC interrupted for > 3 months
Having never been treated with CC (or previous treatment with CC interrupted for > 3 months).
Cannot have received: clomiphene citrate (clomiphene citrate)
Intolerance to CC in previous treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify